Crescent Biopharma Inc (CBIO)

$12.37 +0.25 (2.06%)
Market Cap 168.38M
Revenue (ttm) 794,000.00
Net Income (ttm) -37.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 31,500
Avg Vol 144,062
Day's Range N/A - N/A
Shares Out 13.89M
Stochastic %K 20%
Beta 1.32
Analysts Strong Sell
Price Target $28.20

Company Profile

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates. Its pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics, including novel combinations. The company is headquartered in Waltham, Massachusetts.

Industry: Biotechnology
Sector: Healthcare
Phone: 617-430-5595
Address:
300 Fifth Avenue, Waltham, United States
SuperGreenToday
SuperGreenToday Dec. 17 at 4:50 PM
$CBIO
0 · Reply
Toptradersam
Toptradersam Dec. 13 at 3:03 PM
$ARBB $CBIO $SUI $LRC.X $YEE 📈 Shorts vs bulls, next week could get wild! https://www.youtube.com/watch?v=UntJWC40YL8
1 · Reply
stocktrade77
stocktrade77 Dec. 11 at 7:33 PM
$CBIO entered at 13.9 for a swing to 23
0 · Reply
Glendadunn84
Glendadunn84 Dec. 10 at 1:25 AM
$CBIO ready for bump tomorrow
0 · Reply
Khaled43
Khaled43 Dec. 9 at 9:14 PM
$CBIO $CERO $CHNR $GCTK $ONCO Onco anytime news ——-10+ coming
0 · Reply
Buyitall2024
Buyitall2024 Dec. 8 at 11:20 PM
$CBIO insiders loading open market 🚀
0 · Reply
SocioCobb
SocioCobb Dec. 8 at 11:01 PM
$CBIO open market buys.
0 · Reply
Buyitall2024
Buyitall2024 Dec. 8 at 9:34 PM
$CBIO 18% bought .. 13D released
0 · Reply
deedeethegenius
deedeethegenius Dec. 5 at 6:21 PM
$QCLS $KALA $PMCB $CBIO
0 · Reply
BearTamerTrading
BearTamerTrading Dec. 5 at 1:09 AM
🔥 Recap — Alerted Across All Three Streams Part 1 of 2 🔥 $CEP — Recent volatility & fresh liquidity push 🔥 $CBIO — Biopharma interest + rebound pressure 🔥 $PLRZ — Low-float momentum + early volume pickup 🔥 $AEVA — Tech sector strength + continuation setup 🔥 $SMX — Major breakout fueled by heavy premarket volume All alerted live during today’s sessions — premarket, market hours, and after hours. Strong momentum across the board with multiple profit windows. 🎥 Full Replay: https://www.youtube.com/live/uxeQGYNf2LM?si=f6Fr5L-A87B9M9TO
0 · Reply
Latest News on CBIO
Crescent Biopharma Announces Grants of Inducement Awards

Dec 18, 2025, 4:15 PM EST - 6 days ago

Crescent Biopharma Announces Grants of Inducement Awards

Crescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tumors

Dec 4, 2025, 6:35 AM EST - 20 days ago

Crescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tumors

Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics

Dec 4, 2025, 6:30 AM EST - 20 days ago

Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics

Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 6, 2025, 7:30 AM EST - 6 weeks ago

Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Crescent Biopharma to Present at November Investor Conferences

Nov 5, 2025, 7:30 AM EST - 7 weeks ago

Crescent Biopharma to Present at November Investor Conferences

Crescent Biopharma to Present Preclinical Data for CR-001, a PD-1 x VEGF Bispecific Antibody, at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

Nov 4, 2025, 9:05 AM EST - 7 weeks ago

Crescent Biopharma to Present Preclinical Data for CR-001, a PD-1 x VEGF Bispecific Antibody, at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

Crescent Biopharma to Present at September Investor Conferences

Aug 28, 2025, 7:30 AM EDT - 4 months ago

Crescent Biopharma to Present at September Investor Conferences

Crescent Biopharma: Chasing The Summit Hype

Aug 18, 2025, 11:33 AM EDT - 4 months ago

Crescent Biopharma: Chasing The Summit Hype

Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Jul 31, 2025, 7:34 AM EDT - 5 months ago

Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Crescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific Officer

Jul 8, 2025, 7:30 AM EDT - 6 months ago

Crescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific Officer

Crescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced Private Placement of $200 Million

Jun 16, 2025, 7:00 AM EDT - 6 months ago

Crescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced Private Placement of $200 Million

GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals

Jun 5, 2025, 4:01 PM EDT - 7 months ago

GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals

Crescent Biopharma to Present at the Jefferies Global Healthcare Conference

May 29, 2025, 7:30 AM EDT - 7 months ago

Crescent Biopharma to Present at the Jefferies Global Healthcare Conference

GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYC

May 16, 2025, 1:55 PM EDT - 7 months ago

GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYC

Crescent Biopharma Appoints David Lubner to Board of Directors

Apr 28, 2025, 7:30 AM EDT - 8 months ago

Crescent Biopharma Appoints David Lubner to Board of Directors

Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics

Apr 3, 2025, 7:30 AM EDT - 9 months ago

Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders

Mar 5, 2025, 11:20 AM EST - 10 months ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders

CMRX

Crescent Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

Feb 26, 2025, 8:00 AM EST - 10 months ago

Crescent Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024

Nov 12, 2024, 8:00 AM EST - 1 year ago

Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024

GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting

Nov 6, 2024, 7:00 AM EST - 1 year ago

GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE and GLYC on Behalf of Shareholders

Oct 29, 2024, 11:47 AM EDT - 1 year ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE and GLYC on Behalf of Shareholders

PFIE

GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma

Oct 29, 2024, 7:00 AM EDT - 1 year ago

GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma

GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint

Oct 29, 2024, 6:30 AM EDT - 1 year ago

GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint

GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan

Jul 25, 2024, 9:00 AM EDT - 1 year ago

GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan

GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Jun 4, 2024, 7:00 AM EDT - 1 year ago

GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024

May 29, 2024, 4:01 PM EDT - 1 year ago

GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024

GlycoMimetics, Inc. (GLYC) Corporate Update Call Transcript

May 9, 2024, 3:17 PM EDT - 1 year ago

GlycoMimetics, Inc. (GLYC) Corporate Update Call Transcript

GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

May 6, 2024, 6:00 AM EDT - 1 year ago

GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

GlycoMimetics: Is No News Bad News?

Apr 30, 2024, 7:42 AM EDT - 1 year ago

GlycoMimetics: Is No News Bad News?

GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024

Apr 25, 2024, 7:00 AM EDT - 1 year ago

GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024

GlycoMimetics, Inc. (GLYC) Q4 2023 Earnings Call Transcript

Mar 27, 2024, 10:27 AM EDT - 1 year ago

GlycoMimetics, Inc. (GLYC) Q4 2023 Earnings Call Transcript

GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023

Mar 27, 2024, 7:00 AM EDT - 1 year ago

GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023

GlycoMimetics Can Become A Game Changer In Blood Cancers

Mar 21, 2024, 5:47 PM EDT - 1 year ago

GlycoMimetics Can Become A Game Changer In Blood Cancers

GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024

Mar 13, 2024, 7:00 AM EDT - 1 year ago

GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024

GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference

Feb 26, 2024, 7:00 AM EST - 1 year ago

GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference

GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Feb 12, 2024, 7:00 AM EST - 2 years ago

GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

GlycoMimetics: Drug Approval Is Not Coming In 2024, But The Hype Could Be Real

Jan 30, 2024, 1:04 PM EST - 2 years ago

GlycoMimetics: Drug Approval Is Not Coming In 2024, But The Hype Could Be Real

GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687

Jan 4, 2024, 7:00 AM EST - 2 years ago

GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687

GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia

Dec 10, 2023, 12:00 PM EST - 2 years ago

GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia

GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference

Nov 9, 2023, 7:00 AM EST - 2 years ago

GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference

GlycoMimetics, Inc. (GLYC) Q3 2023 Earnings Call Transcript

Nov 3, 2023, 12:24 PM EDT - 2 years ago

GlycoMimetics, Inc. (GLYC) Q3 2023 Earnings Call Transcript

GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023

Nov 3, 2023, 7:00 AM EDT - 2 years ago

GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023

Catalyst Biosciences Announces Completion of Business Combination With Beijing Continent Pharmaceuticals and Implementation of Name Change and Reverse Stock Split

Oct 30, 2023, 12:00 PM EDT - 2 years ago

Catalyst Biosciences Announces Completion of Business Combination With Beijing Continent Pharmaceuticals and Implementation of Name Change and Reverse Stock Split

GlycoMimetics to Report Third Quarter 2023 Financial Results on November 3, 2023

Oct 20, 2023, 7:00 AM EDT - 2 years ago

GlycoMimetics to Report Third Quarter 2023 Financial Results on November 3, 2023

GlycoMimetics Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687

Sep 6, 2023, 7:00 AM EDT - 2 years ago

GlycoMimetics Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687

GlycoMimetics to Participate in Upcoming H.C. Wainwright 25th Annual Global Investment Conference

Sep 5, 2023, 7:00 AM EDT - 2 years ago

GlycoMimetics to Participate in Upcoming H.C. Wainwright 25th Annual Global Investment Conference

GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Aug 17, 2023, 7:00 AM EDT - 2 years ago

GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlycoMimetics: Q2 2024 Data Readout Makes This Worth A Look, But Cash Is A Problem

Aug 14, 2023, 8:55 AM EDT - 2 years ago

GlycoMimetics: Q2 2024 Data Readout Makes This Worth A Look, But Cash Is A Problem

SuperGreenToday
SuperGreenToday Dec. 17 at 4:50 PM
$CBIO
0 · Reply
Toptradersam
Toptradersam Dec. 13 at 3:03 PM
$ARBB $CBIO $SUI $LRC.X $YEE 📈 Shorts vs bulls, next week could get wild! https://www.youtube.com/watch?v=UntJWC40YL8
1 · Reply
stocktrade77
stocktrade77 Dec. 11 at 7:33 PM
$CBIO entered at 13.9 for a swing to 23
0 · Reply
Glendadunn84
Glendadunn84 Dec. 10 at 1:25 AM
$CBIO ready for bump tomorrow
0 · Reply
Khaled43
Khaled43 Dec. 9 at 9:14 PM
$CBIO $CERO $CHNR $GCTK $ONCO Onco anytime news ——-10+ coming
0 · Reply
Buyitall2024
Buyitall2024 Dec. 8 at 11:20 PM
$CBIO insiders loading open market 🚀
0 · Reply
SocioCobb
SocioCobb Dec. 8 at 11:01 PM
$CBIO open market buys.
0 · Reply
Buyitall2024
Buyitall2024 Dec. 8 at 9:34 PM
$CBIO 18% bought .. 13D released
0 · Reply
deedeethegenius
deedeethegenius Dec. 5 at 6:21 PM
$QCLS $KALA $PMCB $CBIO
0 · Reply
BearTamerTrading
BearTamerTrading Dec. 5 at 1:09 AM
🔥 Recap — Alerted Across All Three Streams Part 1 of 2 🔥 $CEP — Recent volatility & fresh liquidity push 🔥 $CBIO — Biopharma interest + rebound pressure 🔥 $PLRZ — Low-float momentum + early volume pickup 🔥 $AEVA — Tech sector strength + continuation setup 🔥 $SMX — Major breakout fueled by heavy premarket volume All alerted live during today’s sessions — premarket, market hours, and after hours. Strong momentum across the board with multiple profit windows. 🎥 Full Replay: https://www.youtube.com/live/uxeQGYNf2LM?si=f6Fr5L-A87B9M9TO
0 · Reply
jrdicker
jrdicker Dec. 4 at 10:59 PM
$CBIO I assume this will eventually track the stock? Or should I follow $CBIO
0 · Reply
The_Fifteen_Percent_Guy
The_Fifteen_Percent_Guy Dec. 4 at 9:01 PM
✏️ $CBIO Interesting chart formation today > could present an opportunity Fri/Monday.
0 · Reply
Yonatwits
Yonatwits Dec. 4 at 8:24 PM
$CBIO Crescent Biopharma (CBIO): An Emerging Player at the ADC + PD-1/VEGF Intersection The company entered the public markets earlier this year with a strengthened balance sheet and a focused pipeline. 📌 Recent Highlights • Strategic licensing deal with Kelun-Biotech • Crescent obtained ex-China rights to SKB105 ✔ Creates a mutual pathway toward combination development • $185M private placement Provides runway to initiate multiple early-stage studies without immediate dilution pressure 🎯 Why Investors Are Watching 1️⃣ Dual-attack approach on solid tumors: immune + targeted killing 2️⃣ Pipeline no longer depends on a single asset 3️⃣ Very large commercial markets if efficacy translates to the clinic 👀 Upcoming Catalysts to Follow • IND filings and first-in-human study starts for CR-001 & SKB105 • Initial safety readouts (potentially late 2026) • Any expansion of the Kelun relationship or new pharma partnerships • Development of combination study roadmap and solid-tumor indications
0 · Reply
WALTONTRADES
WALTONTRADES Dec. 4 at 6:31 PM
$CBIO looks like whale doesnt need money on this stock even a really big new
0 · Reply
walkingprinter
walkingprinter Dec. 4 at 3:00 PM
$CBIO welcome to the club to all the bag holders
0 · Reply
TA_Kongen
TA_Kongen Dec. 4 at 2:45 PM
$CBIO Is this a fraudster lmfao. Massive sellers on the bid off these 'massive' news? China related?
0 · Reply
Dareing
Dareing Dec. 4 at 2:35 PM
$CBIO good news where are the player makers?
0 · Reply
ProfitTradeRoom
ProfitTradeRoom Dec. 4 at 2:27 PM
🔥 Top 5 stocks this morning: $PLRZ +118% $KALA +58% $PMI +22% $CBIO +17% $QCLS +16%
0 · Reply
Emack529
Emack529 Dec. 4 at 2:24 PM
$CBIO I bought at 19.04 and sold at 15.07. This stock had fantastic news with a private placement. However, the volume is only at 1.3 million 2 hours after news. Contrast that with QCLS which had no news and is at 6.1 million volume. I expect that with such light volume, the shorts will drive this down at market open. But it might pick up strength in AH when volume is lower.
0 · Reply
50shadesoftrades
50shadesoftrades Dec. 4 at 2:21 PM
$PLRZ $KALA $PMI $PMCB $CBIO PM Gappers. this is strange to me the lack of gappers, top two were runners from yesterdays market close.
0 · Reply
Swayz99
Swayz99 Dec. 4 at 2:18 PM
12/4 WL -> $KALA (ww break of PM highs for scalp plays) $QCLS (continuation play, ww break of $6) $PMI (ww back over $3, otherwise leaving it) $CBIO (backburner) Not seeing too much this morning with small caps. Will be watching scanners closely at the open and waiting for those setups. Still remaining very patient in this slow market. Trade the plan. Happy Huntin’!
0 · Reply